Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
CLL Society’s COVID-19 Update for the Week of March 20, 2023
CLL Society is going to lessen the number of COVID-19 Updates to monthly at this time, as all trends in numbers right now seem to be on the downward slope. If (and most likely when) another surge in case numbers occur, we will reassess the need to provide more frequent updates again.
CLL Society’s COVID-19 Update for the Week of March 6, 2023
Please read this week’s update which is pertinent to all of those who are immunocompromised, including anyone living with CLL/SLL regardless of treatment status. The goal of these weekly COVID-19 updates is to keep our community informed of the latest information available.
Dr. Brian Koffman Discusses Shared Decision Making and COVID-19 Management on the Cancer Buzz Podcast
Dr. Brian Koffman explains why shared decision making is particularly important in CLL/SLL at every decision point throughout the course of the disease, and how the pandemic has radically changed the world for CLL patients.
Living with CLL
Chronic Lymphocytic Leukemia Disclosure 101: Who, When, and What to Say About Your Diagnosis, Treatment, and Prognosis
One afternoon in late March 2013, a group of former colleagues and I were making small talk at a memorial service for Steve, who had just died of a brain tumor.
Reducing Sleep disTurbance in Cancer (REST-C)
A major pharmaceutical manufacturer has commissioned market research to understand the unique issues and concerns of those diagnosed CLL.
Your participation in this project will help to expand on new treatments, as well as enhance awareness and improve education about Blood Cancers.
SPECIAL FEATURE: Help Inform CLL Society’s Advocacy Efforts on Health Insurance Issues
CLL Society is actively engaging in important advocacy and policy-related issues for our community. Often, our advocacy efforts on behalf of patients with CLL/SLL extend to health insurance issues, including difficulty in getting insurance to pay for healthcare and treatment-related costs or requiring multiple hurdles before patients can get what they need. These rules for insurance companies differ based on what kind of health insurance one has.
To better understand the health insurance-related issues facing our community, CLL Society is asking for your participation in this short, 2-minute survey to identify your health insurance coverage. Your participation will ensure CLL Society’s advocacy efforts focus on the issues that most significantly impact our community based on the types of health insurance our patients have. Answers to this survey are completely anonymous.
This survey is exclusively for patients with CLL/SLL. Please complete the survey for yourself as an individual living with CLL/SLL or complete it on behalf of your loved one who is a CLL/SLL patient.
CLL Society Partners with the All Copays Count Coalition Regarding the Proposed ‘HELP Copays Act’
CLL Society remains hard at work behind the scenes on important advocacy and policy issues that impact those in our community. We recently worked with our partners at the All Copays Count Coalition, signing onto a joint letter to members of the US House of Representatives regarding the “Help Ensure Lower Patient Copays Act” (HELP Copays Act). The proposed bipartisan act would require healthcare plans to count any funds that patients receive from medication copay assistance programs towards their annual capped out-of-pocket expense amount.
Wednesday, April 12, 2023 at 9:30 AM PT / 12:30 PM ET
The Importance of Front-Loading Your Knowledge During the Early Journey of CLL/SLL
CLL/SLL is a complicated chronic disease to understand, and there is so much to learn. CLL Specialist, Dr. Joanna Rhodes will explain diagnostic and prognostic testing, the importance of obtaining vaccinations before disease progression, managing emotions and anxiety after finding out you have blood cancer, and other tips for maintaining your overall health. CLL patient advocate Stephen Feldman will share important resources and help moderate your questions.
If you missed the recent Facebook Live Event, watch the replay now: “Ask Me Anything” – Featuring Dr. Brian Hill and Jeff Folloder!
If you missed the recent webinar on the latest research from ASH 2022 and what it means for people with CLL/SLL with Drs. Sameer Parikh and Brian Koffman, you can catch the replay of ASH 2022 Comes to You here!
ASH 2022: Dr. Neil Kay on Senescence in CAR-T Cells
This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.
ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year
Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).
ASH 2022: NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
Tremendous progress over the past decade has been made in managing chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Equitable Access and Regulatory News
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
On 1/27/23 [email protected] announced the Federal Drug Administration (FDA)’s accelerated approval of pirtobrutinib in adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least 2 lines of systemic therapy, including a BTK inhibitor.